Qube Research & Technologies (QRT)
KYMR icon

Qube Research & Technologies (QRT)’s Kymera Therapeutics KYMR Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-59,709
Closed -$2.83M – 3670
2024
Q3 		$2.83M Buy
59,709
+50,323
+536% +$2.22M ﹤0.01% 1620
2024
Q2 		$280K Buy
+9,386
New +$325K ﹤0.01% 2332
2023
Q4 		– Sell
-50,785
Closed -$706K – 4558
2023
Q3 		$706K Buy
50,785
+4,596
+10% +$92.4K ﹤0.01% 1880
2023
Q2 		$1.06M Buy
46,189
+37,810
+451% +$1.08M ﹤0.01% 1278
2023
Q1 		$248K Sell
8,379
-18,623
-69% -$601K ﹤0.01% 1848
2022
Q4 		$674K Sell
27,002
-44,370
-62% -$1.18M ﹤0.01% 1372
2022
Q3 		$1.55M Buy
+71,372
New +$1.88M 0.01% 1034
2021
Q3 		– Sell
-13,143
Closed -$637K – 2519
2021
Q2 		$637K Buy
+13,143
New +$571K 0.01% 1156
2020
Q4 		– Sell
-7,658
Closed -$247K – 2025
2020
Q3 		$247K Buy
+7,658
New +$234K ﹤0.01% 1322

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Qube Research & Technologies (QRT)'s KYMR Position: Q4 2024 in Review

Qube Research & Technologies (QRT) sold out of Kymera Therapeutics (KYMR) in Q4 2024, closing a stake of 59,709 shares — an estimated $2.83M sold.

Qube Research & Technologies (QRT) first reported a position in KYMR in Q3 2020 and held it in 9 quarters. The position peaked at $2.83M in Q3 2024. 180 funds tracked by Wall St. Rank hold KYMR as of Q4 2024.

  • Qube Research & Technologies (QRT) reported no remaining Kymera Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 59,709 Kymera Therapeutics shares in Q4 2024, an estimated $2.83M.
  • Qube Research & Technologies (QRT) first reported a position in Kymera Therapeutics in Q3 2020 and held it in 9 quarters.
  • Qube Research & Technologies (QRT)'s Kymera Therapeutics position peaked at $2.83M in Q3 2024.
  • 180 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2024, filed 14 Feb 2025.